White House denies report that Trump obtained experimental obesity drug retatrutide under compassionate use program.
Stat News reported that a 79-year-old man with high-level connections received FDA approval for retatrutide, an experimental Eli Lilly obesity drug, on a compassionate use basis. The White House denied the application was for President Trump, calling the reporter an "unserious gossip columnist."
17
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
HuffPost
The Hill
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
HuffPost leans into the pattern of pulling strings for rare treatments, while The Hill keeps it to a White House bats down speculation denial.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“White House bats down speculation that Trump got access to Eli Lilly obesity drug for 'compassionate use'”
“It Kinda Looks Like Trump Might Be Taking An Experimental Obesity Drug?”
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed